Morgan Stanley Downgrades Merck (MRK) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Morgan Stanley Downgrades Merck (MRK) to Equalweight
May 8, 2014 6:49 AM EDT
BMO Capital downgraded Merck (NYSE: MRK) from Outperform to Market Perform with a price target of $60.00 (from $63.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $55.84 yesterday.
...
More
May 6, 2014 11:40 AM EDT
Moody's Investors Service commented that the $14.2 billion sale of Merck & Co., Inc.'s (NYSE: MRK) consumer products business to Bayer AG is credit positive for Merck. There is no impact on Merck's ratings, which include the A1 senior unsecured long-term rating (on guaranteed... More
May 6, 2014 11:13 AM EDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the companys research facility in Boston. The briefing is also available via webcast at www.merck.com starting at 9:00 a.m. EDT.
Members of the companys senior management team provided updates on the progress Merck has made on its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, bolster its innovative pipeline and accelerate efforts to redesign its operating model and reduce its cost base.
New, Focused... More
